Japan Oncology Therapeutics Market Report 2022 to 2030

Japan Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Japan Oncology Therapeutics Market will reach a value of $22.3 Bn from $11.2 Bn in 2022, growing at a CAGR of 8.9% during 2022-2030. The Oncology Therapeutics Market in Japan is dominated by a few domestic pharmaceutical companies such as Takeda Pharmaceutical, Daiichi Sankyo, and Astellas Pharma. The Oncology Therapeutics Market in Japan is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Japan Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10JPPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Vishwa Modhia

Buy Now

Japan Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Japan Oncology Therapeutics Market will reach a value of $22.3 Bn from $11.2 Bn in 2022, growing at a CAGR of 8.9% during 2022-2030.

Japan is a high-income developed island nation in East Asia. Cancer treatment consumes 7.3% of all healthcare resources. This is higher in Japan than in other countries. Prostate and lung cancer therapies will dominate the Japanese cancer drug market in the approaching years, owing to the country's huge geriatric population. Cancer has been the main cause of death in Japan for more than 30 years, and the mortality rate continues to rise year after year. Tobacco smoking has been linked to a variety of malignancies. In Japan, the population attributable fraction (PAF) of cigarette smoking to cancer was 24 %, infection was 22 %, alcohol drinking was 6 %, and salt over-consumption was 1.4 %. Japan's government spends 10.3% of its GDP on healthcare.

Japan Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Because Japan spends less on healthcare than other wealthy countries, therapies for diseases such as cancer are less expensive and more efficient. The Japanese government will also play a crucial role in the rapid growth of the cancer drug market by providing a supportive policy environment for uncomplicated drug approval, manufacture, and product marketing. The Pharmaceuticals and Medical Devices Agency (PMDA) will soon approve several new cancer-targeting drugs. There are now 1617 cancer-related clinical trials in Japan including more than 350 cancer medicines, with approximately 30% of these trials in the late phases of research. According to the 2017 Japanese Structure Survey of Radiation Oncology conducted by the Japanese Society for Radiation Oncology, radiation treatment was used to treat a total of 185,523 patients. These aspects could boost Japan Oncology Therapeutics Market.

Market Restraints

As of 2021, Japan had 1322 board-certified radiation oncologists and 1337 board-certified medical physicists, but there is still a significant lack of these specialists, particularly at small-scale hospitals. In Japan, the lack of contemporary cancer therapies limits your options and your ability to fight the disease. As a result of this restriction, many Japanese cancer patients seek treatment outside of the country's public healthcare system. This is regrettable since, despite the country's reputation for having a largely healthy populace, cancer is nevertheless highly common in Japan. These factors may deter new entrants into the Japan Oncology Therapeutics Market.

Competitive Landscape

Key Players

Takeda Pharmaceutical Company: Takeda is a Japanese pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs, targeted therapies, and biologics
Daiichi Sankyo: Daiichi Sankyo is a Japanese pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs, targeted therapies, and biologics
Chugai Pharmaceutical
Astellas Pharma

Notable Recent Deals

December 2022: Imfinzi (durvalumab) and Imjudo (tremelimumab) by AstraZeneca have been licenced in Japan for the treatment of three cancer types: advanced liver, biliary tract, and lung. Imfinzi, in combination with Imjudo, is approved for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) and adult patients with unresectable, advanced, or recurring non-small cell lung cancer (NSCLC) in conjunction with chemotherapy. Imfinzi has also been approved for the treatment of adult patients with unresectable HCC as monotherapy, as well as adult patients with curatively unresectable biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

September 2022: Daiichi Sankyo has been concentrating on a stable of antibody-drug conjugates, and the Japanese firm has achieved a global first in this field. Daiichi Sankyo has received Japanese approval for Ezharmia, also known as valemetostat (DS-3201), to treat relapsed or refractory adult T-cell leukaemia/lymphoma (ATL). With this approval, Ezharmia becomes the first EZH1/2 dual inhibitor to get regulatory approval anywhere in the globe.

Healthcare Policies and Reimbursement Scenarios

In Japan, the administrative body answerable for the endorsement and guideline of remedial items, including disease therapeutics, is the Pharmaceuticals and Medical Devices Agency (PMDA).In the public medical services framework, the expense of malignant growth therapies, including disease therapeutics, is covered by the National Health Insurance (NHI) framework. The repayment of disease therapeutics under the NHI framework in Japan is dependent upon the valuing framework set by the Ministry of Health, Labour and Welfare (MHLW). The MHLW lays out evaluating principles in view of the clinical viability and well-being of the medication and cost-adequacy examination.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.